Unlike the mechanisms of other enzyme systems, amino acid conjugation involves multiple enzymes. Carboxylic acids are activated by conjugation to acetyl-CoA via acetyl-CoA synthetase (EC 126.96.36.199) present in mitochondria. This is followed by enzymatic conjugation with amino acids such as glycine, glutamate, and taurine.
Balani SK, Zhu T, Yang TJ et al (2002) Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos 30:1059-1062 Barski OA, Tipparaju M, Bhatnagar A (2008) The aldo-keto reductase super-family and its role in drug metabolism and detoxification. Drug Metab Rev 40(4):553-624
Benedetti MS, Whomsley R, Baltes E (2006) Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2:895-921 Cashman JR (2008) Role of flavin-containing monooxygenase in drug development. Expert Opin Drug Metab Toxicol 4(12):1507-1521 Diamond S, Boer J, Maduskuie T et al (2010) Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277-1285 Draganov DI, Teiber JF, Speelman A et al (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46:1239-1247 Driscoll JP, Aliagas I, Harries JJ, Halladay JS, Khatib-Shahidi S, Deese A, Segraves N, Khojasteh-Bakht SC (2010) Formation of a quinoneimine intermediate of 4-fluoro-N-methylaniline by FMO1: carbon oxidation plus defluorination Chem Res Tox 23(5):861-863 Janmohamed A, Hernandez D, Phillips IR, Shephand (2004) cell-, tissue, sex- and developmental stage-specific expression of mous flavin-containing monooxygenases (Fmos) Biochem Pharmacol 68(1)73-83 Martignoni M, Groothuis GM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894
Mathew N, Muthuswami Kalyanasundaram M, Balaraman K (2006) Glutathione S-transferase (GST) inhibitors. Expert Opin Ther Pat 16: 431-444
Morisseau C, Hammock BD (2005) Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45:311-333
Obach RS, Huynh P, Allen MC, Beedham C (2004) The human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19 Oleson L, Court MH (2008) Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant uDP-glucuronosyltransferases. J Pharm Pharmacol 60:1175-1182
Paine MF (2006) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886
Redinbo MR, Bencharit S, Potter PM (2003) Human carboxylesterase 1: from drug metabolism to drug discovery. Biochem Soc Trans 31:620-624 Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29(1-2):413-580
Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6(2):140-148 Torres RA, Korzekwa KR, McMasters DR et al (2007) Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase. J Med Chem 50:4642-4647 Uchaipichat V, Mackenzie PI, Elliot DJ et al (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos 34(3):449-456 van Himbergen TM, van Tits LJH, Roest M et al (2006) The story of poN1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 64(2):34-38 Vaz ADN, Pernecky SJ, Raner GM et al (1996) Peroxo-iron and oxenoid-iron species as alternative oxygenating agents in cytochrome P450-catalyzed reactions: switching by threonine-302 to alanine mutagenesis of cytochrome P450 2B4. Proc Natl Acad Sci USA 93:4644-4648 Williams RT (1959) Detoxication mechanisms: the metabolism and detoxification of drugs, toxic substances and other organic compounds. Wiley, New York
Williams JA, Hyland R, Jones BC et al (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208 Zhang J, Cashman JR (2006) Quantitiative analysis of FMO gene mRNA
levels in human tissues. Drug Metab Dispos 34:19-26 Zientek M, Jiang Y, Youdim K et al (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322-1327
Ortiz de Montellano PR (ed) (2004) Cytochrome P450: structure, mechanism, and biochemistry, 3rd edn. Kluwer Academic/Plenum, New York Parkinson A, Ogilivie BW (2007) Biotransformation of xenobiotics. In: Klaassen CD (ed) Casarett & Doull's toxicology: the basic science of poisons, 7th edn. McGraw-Hill, New York Testa B, Krämer SD (2010) The biochemistry of drug metabolism: two volume set. Wiley-VCH, Weinheim, Germany Uetrecht JP, Trager W (2007) Drug metabolism: chemical and enzymatic aspects. Informa Healthcare, New York
Was this article helpful?